-
Barron's Picks And Pans: CVS, Disney, McDonald's, Noble Energy And More
Saturday, April 13, 2019 - 1:13pm | 500Read More...This weekend's Barron's cover story offers a look at a company set to shake up health care. Other featured articles examine prospects for oil drillers as takeover targets and for dividend growth stocks. Also, a recent health care spin-off and the newest livestreaming titan. "Can CVS...
-
Cowen Downgrades Novartis, Strengths 'Now Balance Its Risks'
Wednesday, April 5, 2017 - 11:36am | 347Read More...Steve Scala of Cowen downgraded shares of Novartis AG (ADR) (NYSE: NVS) from Outperform to Market Perform with a price target lowered to $77 from $87 as the company's strengths "now balance its risks." According to Scala's estimates, Novartis' earnings per share growth from...
-
Bernstein Lists Active Buyers Of Ophthalmology Companies
Thursday, June 9, 2016 - 1:12pm | 287Read More...Allergan plc Ordinary Shares (NYSE: AGN), Alcon, Shire PLC (ADR) (NASDAQ: SHPG) and, to a lesser extent, Bausch & Lomb are the active buyers of ophthalmology products/companies, according to a note from Bernstein citing venture capitalist Emmett Cunningham. Of note, Alcon is a subsidiary of...
-
Glaukos: What Data Points Really Matter?
Friday, April 22, 2016 - 3:50pm | 277Read More...Piper Jaffray said it values Glaukos Corp (NYSE: GKOS)'s suprachoroidal stent in development at $175 million based on Alcon's announcement that it paid $352 million for Glaukos competitor, Transcend, which also has a similar product. Analyst Matt O'Brien said Transcend's CyPass...
-
Novartis Joins Google To Develop Contacts For Diabetics
Friday, July 18, 2014 - 8:59am | 606Read More...Development of devices and mobile applications in the health care sector has exploded of late. Now, according to The New York Times, drugmaker Novartis (NYSE: NVS) is collaborating with Google (NASDAQ: GOOG) (NASDAQ: GOOGL) to develop a smart contact lens that would constantly monitor the blood...
-
Markets Mixed, NASDAQ Lower As Yellen Suggests Valuations Are Stretched
Tuesday, July 15, 2014 - 3:35pm | 2480Read More...U.S. stocks were mixed with the NASDAQ index declining after the Fed's Chief Janet Yellen suggested that some sectors are characterized by "stretched" valuations. In prepared remarks to the Senate Banking Committee, Yellen also claimed that interest rates could rise sooner and at...
-
Piper Jaffray Discontinues Coverage on Alcon (ACL)
Thursday, March 17, 2011 - 7:26am | 145Read More...Piper Jaffray is out with its report today on Alcon (NYSE: ACL), discontinuing coverage on shares of ACL. In a note to clients, Piper Jaffray writes, "On December 15, 2010, Alcon and Novartis agreed to a merger agreement whereby Novartis will acquire the 23% of Alcon shares it does not currently...
-
Citigroup Downgrades Alcon To Hold
Thursday, January 20, 2011 - 6:50am | 27Read More...Citigroup has downgraded Alcon, Inc. (NYSE: ACL) from Buy to Hold and has lowered the price target from $181 to $168.
-
Novartis Poised for Growth Despite Concerns
Monday, November 15, 2010 - 11:55am | 200Read More...Barron's is reporting that Novartis should outperform over the next two years despite the loss of patents and concerns over their purchase of a majority stake in Alcon (NYSE: ACL). Novartis purchased a 77% stake in Alcon for $38.7B this year. Observers are concerned by "potential dilution as...
-
Jefferies & Company Raises Alcon Estimates
Friday, October 22, 2010 - 7:49am | 89Read More...Jefferies & Company is raising its estimates of Alcon, Inc. (NYSE: ACL) to reflect another solid quarter. The company said that its Hold Rating strictly reflects expectations for single-digit returns into the final merger negotiations. “We continue to view the final price tag for the minority...
-
3Q Upside For Medical Tech. & Hospital Supplies
Thursday, October 14, 2010 - 6:16am | 196Read More...Piper Jaffray has published a research report on Medical Technology and Hospital Supplies as sales continue to track above expectations, as witnessed in September earnings results. In the report, Piper Jaffray writes "JNJ: Tracking $24 MM ahead of expectations - Upside in Q3 is being driven...
-
ACL, JNJ Beating 3Q Estimates
Thursday, September 30, 2010 - 6:29am | 140Read More...Piper Jaffray prefers stocks that have potential for greater upsides, and has thus remained Neutral on both Alcon, Inc. (NYSE: ACL) and Johnson & Johnson (NYSE: JNJ). In the research report, Piper Jaffray writes "For ACL, the company is benefiting from pricing gains, as well as low single digit...
